Maryland wants to pay Medicare's price for some drugs. We priced seven of them.

6 min read

Share

A felt balance scale.

Free State, not free drugs: what Maryland's Medicare-price plan would change

Maryland's governor is backing a bill to pay Medicare's negotiated price for some brand-name drugs. Here is what those prices are, and what a person paying cash can find today.

The short answer: the bill would let Maryland's drug board cap what certain health plans pay for a drug at the price Medicare negotiated. It does not set the price you pay at the counter. We compared Medicare's price for seven common drugs with their list prices and with public cash prices. For three of them, a cash option already costs less than Medicare's 2026 price. For three others, the best cash price we found was 26.4% to 49.4% higher than Medicare's negotiated price.

What Maryland is proposing

Maryland Matters reported on October 15, 2026, in a story by Danielle J. Brown republished by the Baltimore Sun, that Gov. Wes Moore backs legislation letting the state's Prescription Drug Affordability Board set "upper payment limits" based on the Maximum Fair Price that Medicare negotiates with drugmakers. Moore promised to sign the bill, assuming it survives the 2027 legislative session.

The bill would at least shorten the board's months-long review for the 25 drugs Medicare has already negotiated, the 15 now in negotiation, and future ones. "Under this bill, when Medicare negotiates what it pays for a drug, Maryland can pay the same once our board signs off," Moore said.

Some limits are already coming. The board approved upper payment limits for Jardiance and Ozempic that take effect in January 2027. For Ozempic, board staff recommended a limit equal to Medicare's 2027 price, $274 for a 30-day supply, and noted that Maryland's rules do not allow a limit below Medicare's price. Today the board's authority covers only state health plans, meaning state employees and incarcerated individuals. It is set to expand to private insurance in 2028.

PhRMA, the drug industry's trade group, opposes the approach. Spokesman Will May said, "Government price-setting creates uncertainty for patients and risks limiting access to medicines."

Seven drugs, four prices

Medicare's negotiated price comes from CMS. List price is the wholesale price a drugmaker sets before discounts. Cash prices are what each program or pharmacy posts for someone paying out of pocket.

Drug (what we priced)Medicare price, 2026Medicare price, 2027List price when negotiated (CMS)List price nowPublic cash price
Jardiance, 10 or 25 mg, 30 tablets$197$202.33$573 (2023)$350 (Boehringer Ingelheim, Jan. 1, 2026)$249 brand, Boehringer Ingelheim Direct, for people with no drug coverage
Farxiga, 10 mg, 30 tablets$178.50$183.33$556 (2023)$377.82 (TrumpRx)$35 brand, AstraZeneca Direct via TrumpRx; generic dapagliflozin $7.43 at Cost Plus Drugs
Januvia, 30 tablets$113$116.06$527 (2023)$330 for 25 or 50 mg (TrumpRx)$84.57 brand 25 or 50 mg, Merck via TrumpRx; generic sitagliptin 100 mg $40.89 at Cost Plus Drugs
Eliquis, 5 mg twice daily, 60 tablets$231$237.25$521 (2023)$346 (Bristol Myers Squibb, Jan. 2026)$345 brand, Eliquis 360 Support direct-to-patient
Xarelto, 20 mg, 30 tablets$197Leaves the program Jan. 1, 2027$517 (2023)$611.82 (TrumpRx)$197 brand, J&J Direct via TrumpRx
Entresto, 97/103 mg twice daily, 60 tablets$295Leaves the program Jan. 1, 2027$628 (2023)Not foundGeneric sacubitril/valsartan $10.87 at Cost Plus Drugs
Ozempic, 1 mg weekly, 1 penNone (price starts 2027)$274$959 (2024)$1,027.51 (TrumpRx)$349 brand, NovoCare Pharmacy self-pay

Assumptions: a 30-day supply at the dose shown, prices checked October 19, 2026. Cost Plus prices include its $5 dispensing fee; standard shipping adds $5.25. TrumpRx labels its "original price" as the wholesale acquisition cost, which is the list price. Ozempic's $349 covers the 0.25, 0.5, and 1 mg doses; NovoCare charges $499 for 2 mg and $199 for each of a new patient's first two fills at 0.25 or 0.5 mg through December 31, 2026.

What the table shows

  • List prices have dropped. Eliquis, Jardiance, Farxiga, and Januvia list prices now sit 32.0% to 38.9% below what CMS reported when it negotiated. Xarelto and Ozempic list prices went up.
  • Generics beat Medicare's price. Generic dapagliflozin costs 95.8% less than Medicare's 2026 Farxiga price, and generic sacubitril/valsartan costs 96.3% less than Medicare's Entresto price. Xarelto and Entresto leave Medicare's negotiation program on January 1, 2027, CMS says, which happens when generics reach the market. A Maryland cap tied to Medicare's price would no longer apply to them.
  • Some cash prices still run above Medicare. The best cash prices we found for Eliquis, Jardiance, and Ozempic are 49.4%, 26.4%, and 27.4% higher than Medicare's price. Xarelto's $197 cash price matches Medicare's 2026 price exactly.
  • Medicare's price is not your copay. Bristol Myers Squibb's Eliquis page says the negotiated price is what the government pays and does not set what Medicare patients pay; that is set by your plan.

If you pay a lot for one of these drugs

  • Ask about manufacturer programs. Six of the seven brands in the table have a maker's cash program; we found none for Entresto. Most cash offers are for uninsured or self-pay patients, and the copay cards we read exclude Medicare. Read the eligibility terms before you switch.
  • Compare pharmacy cash prices. The same drug can cost very different amounts at different pharmacies. If a generic is listed, ask your prescriber or pharmacist whether it fits your prescription.
  • On Medicare Part D, start with your plan. Your plan's rules, not the negotiated price, set what you pay. A cash offer you use outside your plan may not count toward your deductible or yearly out-of-pocket limit.
  • Talk with your prescriber before you change a drug, dose, or brand.

Where Temi fits

Temi does not sell these medicines and has no price for them. If you already take a non-controlled medicine and need a refill prescription, a licensed physician reviews your request within 48 hours, often sooner. The review costs $15, or $0 with Temi Care. If approved, the prescription goes to the pharmacy you choose, and you pay that pharmacy for the medicine, with insurance, a discount card, or cash. Temi serves patients located in Arizona, California, Colorado, Delaware, Florida, Michigan, Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas, and Wisconsin. It does not serve Maryland today. See how refills work.

Sources

Editorial Standards

This article has not been reviewed by a licensed physician. We cite peer-reviewed studies, academic research institutions, and medical associations. Our sources are listed at the end of each article.

If you notice an error or have a concern about our content, please email supportusetemi.com.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.

Felt Temigami re-enacting famous revolutions, from crossing the Delaware to raising a pill-bottle flag.

The revolution will be emailed.

Once a week, roughly. We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy

Temi

Start online, and a licensed physician reviews your request

See if you qualify

A licensed physician reviews every request. Nothing on this page is a prescription.